Customization: | Available |
---|---|
CAS No.: | 33818-15-4 |
Formula: | C14h25n4nao11p2 |
Still deciding? Get samples of US$ 0/Bag
Request Sample
|
Suppliers with verified business licenses
Audited by an independent third-party inspection agency
Model NO. | Citicoline Sodium |
Assay | >98.0% |
Specification | >99% |
Transport Package | 1~5kg/Bag, 25kg/Drum |
Origin | CHINA |
Trademark | ANHUI |
HS Code | 29349990 |
Product name | Citicoline Sodium |
CAS No. | 33818-15-4 |
Appearance | A white crystalline or crystalline powder |
Purity ( HPLC ) | 98.0% to102.0% |
Shelf life | 24 months |
Packing | 25kg/drum |
Loss on drying | Not more than 6% |
Specification | 99% |
Citicoline sodium, as a neuroprotective agent, can quickly repair damaged neuron cell membranes, increase cerebral blood flow, promote energy metabolism in the brain, and improve cerebral circulation. The curative effect of the disease is certain, and it is currently the best-selling drug in the clinical treatment of brain diseases.
Citicoline sodium is an activator of brain metabolism, which can promote brain cell respiration, improve brain function, promote recovery, and reduce cerebrovascular resistance. It can not only treat neurological diseases caused by craniocerebral injury and cerebrovascular accident, but also Adjuvant therapy for Kinsen's syndrome and Alzheimer's disease has obvious clinical effects on acute stroke, nerve damage and disturbance of consciousness after surgery, and also improves amblyopia, strabismus, and glaucoma.
The administration routes of citicoline sodium include oral administration, intravenous drip and intramuscular injection. In fact, oral administration can be completely absorbed, so its bioavailability is almost the same as that of intravenous administration. It can be widely distributed in various parts of the body, and it can enter the central nervous system through the blood-brain barrier.
1. Brain metabolic activators
2. Boost brain cell respiration
3. Improve circulation
4. Promoting arousal
5. Reducing cerebrovascular resistance
brain diseases; neurological disorder; Parkinson's disease; glaucoma
Citicoline Sodium is a multimodal agent that has demonstrated neuroprotective and neurodegenerative effects in various experimental and clinical disorders of the central nervous system, including acute and chronic cerebral ischemia, cerebral hemorrhage, and global cerebral hypoxia. It provides neuroprotection by attenuating glutamate excitotoxicity, oxidative stress, apoptosis, and blood-brain barrier dysfunction.
In recent years, in addition to being used in brain surgery and traumatic brain injury, it has also been used in the auxiliary treatment of function and consciousness, tremor paralysis, tinnitus and nervous deafness, glaucoma, and amblyopia caused by acute injury of the central nervous system.
Citicoline Sodium may also act as an adjuvant therapy and prevent cognitive decline and other neurological complications associated with disease 2019.
CDPC can be administered intravenously, intramuscularly, or orally: after administration, citicoline sodium is catabolized relatively quickly and is the source of choline in the blood. After oral administration, citicoline sodium is rapidly absorbed and then hydrolyzed into choline and cytidine in the intestinal wall and liver; thus, in addition to providing metabolic precursors of phospholipids, it also enters the synthesis pathways of nucleic acids, proteins, and acetylcholine.
Today, Citicoline Sodium is available as an oral, intravenous infusion, intramuscular injection, and eye drops.